Consolidated Statement Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Net cash flows from operating activities:
Net income	$ 7,371	$ 3,944	$ 8,679
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	4,960	3,937	4,263
Non-cash compensation	2,790	2,621	2,429
Deferred income taxes	1,767	(1,509)	5,254
Excess tax shortfall (benefit) from stock based compensation	445	(1,275)
Write-down of deferred preservation costs and inventories	270	2,093	489
Write-down of intangible asset	255	921
Other than temporary investment impairment		3,638
Acquired in-process research and development expense		3,513
Gain on valuation of derivative		(1,345)	(24)
Other non-cash adjustments to income	67	185	187
Changes in operating assets and liabilities:
Receivables	(2,230)	179	(745)
Deferred preservation costs and inventories	2,445	3,098	(1,140)
Prepaid expenses and other assets	(617)	(1,539)	(353)
Accounts payable, accrued expenses, and other liabilities	(772)	2,376	(2,467)
Net cash flows provided by operating activities	16,751	20,837	16,572
Net cash flows from investing activities:
Acquisition of Cardiogenesis, net of cash acquired	(21,062)
Acquisition of PerClot intangible assets		(5,411)
Capital expenditures	(2,538)	(2,121)	(1,690)
Purchases of restricted securities and investments	(3,569)	(2,705)	(3,036)
Sales and maturities of marketable securities			1,130
Other	(547)	(497)	(783)
Net cash flows used in investing activities	(27,716)	(10,734)	(4,379)
Net cash flows from financing activities:
Proceeds from financing of insurance policies		1,179	1,272
Principal payments on debt, capital leases, and short-term notes payable	(31)	(1,537)	(1,328)
Proceeds from exercise of stock options and issuance of common stock	694	239	1,093
Repurchase of common stock	(3,064)	(5,877)	(330)
Excess tax (shortfall) benefit from stock based compensation	(445)	1,275
Net cash flows (used in) provided by financing activities	(2,846)	(4,721)	707
(Decrease) increase in cash and cash equivalents	(13,811)	5,382	12,900
Effect of exchange rate changes on cash	19	(6)	20
Cash and cash equivalents, beginning of year	35,497	30,121	17,201
Cash and cash equivalents, end of year	$ 21,705	$ 35,497	$ 30,121